Fc and Glycoengineered Antibodies Market: Industry Trends and Global Forecasts, till 2035: Distribution by Type of Engineering, Type of Therapy, Therapeutic Area, Route of Administration and Key Geographical Regions

Fc and Glycoengineered Antibodies Market Experiences Over 30% Growth in Collaborations in Past Two Years, Fueled by Strategic Partnerships

The global Fc and glycoengineered antibodies market is estimated to be worth US$ 38.8 billion in 2024. The new research study consists of industry trends, detailed Fc and glycoengineered antibodies market analysis, key market insights, market impact analysis, market forecast and opportunity analysis. The growth in the opportunity for drug developers over the next decade is likely to be the result of anticipated increase in patient population and rise in the demand for Fc and glycoengineered antibodies.

Antibody based pharmacological interventions have become one of the fastest growing segments of the biopharmaceutical industry, with over 120 approved monoclonal antibodies, and close to 900 registered trials for clinical evaluation. In fact, it is worth highlighting that, these interventions are expected to contribute to the global sales surpassing USD 300 billion by 2025.

The therapeutic efficacy of a drug determines its ability to produce the desired therapeutic effects in treating a particular disease. A drug with high therapeutic efficacy improves treatment outcomes by increasing target specificity, reducing side-effects and extending half-life of the drug. Therefore, in order to enhance the therapeutic efficacy of antibodies, various Fc and glycoengineering strategies have been developed recently. Fc engineering increases the effector functions (such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC)) and half-life of the molecule by modifying their Fc regions. On the other hand, glycoengineering optimizes pharmacokinetic and pharmacodynamic properties of therapeutic antibodies by controlling glycan composition in the molecule. These engineered antibodies are widely used in enhancing anti-tumor potential of monoclonal antibodies.

Currently, several drug developers, along with technology providers in this domain are actively developing various Fc and glycoengineered antibodies. In addition, several big pharma players have also demonstrated their interest in these engineered antibodies and are investing both time as well as capital in Fc and glycoengineered antibodies market. Presently, over 150 Fc and glycoengineered antibodies have been approved globally. Notable examples of recently approved products (in 2023) include Retifanlimab, Elranatamab, Glofitamab and Tislelizumab.

Owing to the promising antibody based drug pipeline and ongoing technical advancements, coupled with the growing interest of biopharmaceutical developers, we believe that the Fc and glycoengineered antibodies market is likely to witness a commendable market growth during the forecast period.

Fc and Glycoengineered Antibodies Market Share Insights

The market research report presents an in-depth analysis of the various firms / organizations in the Fc and glycoengineered antibodies industry, across different segments, as defined below:

• Historical Trend: 2019-2023
• Base Year: 2023
• Forecast Period: 2024-2035
• Market Size 2024: $38.8 Billion
• Market Size 2035: $ 38.7 Billion
• PowerPoint Presentation (Complimentary)
• Customization Scope: 15% Free Customization
• Type of Engineering
  • Fc Engineered Antibodies
  • Glycoengineered Antibodies
• Type of Therapy
  • Monotherapy
  • Combination Therapy
  • Both
• Therapeutic Area
  • Autoimmune Disorders
  • Dermatological Disorders
  • Oncological Disorders
  • Rare Diseases
  • Other Disorders
• Route of Administration
  • Intravenous Route
  • Subcutaneous Route
  • Intramuscular Route
• Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Key Companies Profiled
  • AbbVie
  • Akesobio
  • Alexion Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Boehringer Ingelheim
  • Genentech
  • MacroGenics
  • MorphoSys
  • Kyowa Kirin
  • Xencor
  • (Full list of close to 35 companies captured is available in the report)
• Excel Data Packs (Complimentary):
  • Market Landscape
  • Clinical Trial Analysis
  • Partnerships and Collaborations
  • Grant Analysis
  • Patent Analysis
  • Market Forecast and Opportunity Analysis

Fc and Glycoengineered Antibodies Market Segmentation Overview

Market Share by Type of Fc Engineering

The global Fc and glycoengineered antibodies market is segmented into Fc engineered and glycoengineered antibodies, based on the type of engineering. Currently, the Fc engineered antibodies segment captures the highest share in 2024 and is likely to dominate the market in the future as well. This can be attributed to the fact that Fc engineering enhances the effector functions, thereby improving therapeutic efficacy of the modality.

Market Share by Type of Therapy

Based on the type of therapy, the global Fc and glycoengineered antibodies market is segmented into monotherapy and combination therapy. The monotherapy segment occupies the highest share in 2024 and is expected to dominate the overall market, during the forecast period. This can be attributed to the fact that monotherapy is a preferred option for various patients and healthcare providers, owing to their easy regulatory pathways, reduced potential drug interactions and cost effectiveness.

Market Share by Therapeutic Area

Based on the therapeutic area, the global Fc and glycoengineered antibodies market is segmented into autoimmune disorders, dermatological disorders, infectious diseases, gastrointestinal disorders, neurological disorders, oncological disorders, pulmonary disorders and rare diseases. The oncological disorders segment occupies the highest share in 2024. However, the autoimmune disorders market segment is expected to witness substantial market growth in the coming years.

Market Share by Route of Administration

Based on the route of administration, the global Fc and glycoengineered antibodies market is segmented into intravenous, subcutaneous and other routes of administration. The intravenous route segment captures the highest share in 2024 and is expected to remain dominant during the forecast period. This can be primarily attributed to the fact that intravenous route offers complete systemic distribution of antibodies, enhancing therapeutic efficacy and bioavailability. Further, this route enables precise control over dosage, making it a preferred route of administration for many therapeutic antibodies.

Market Share by Key Geographical Regions

This segment highlights the distribution of Fc and glycoengineered antibodies market across key geographical regions, such as North America, Europe, Asia-Pacific and Rest of the World. According to the projections, the market in North America is likely to capture majority (67%) of the share, and this trend is unlikely to change in the future. It is worth highlighting that the market in Asia-Pacific is likely to grow at a relatively higher CAGR (2.0%), during the period 2024-2035.

Fc and Glycoengineered Antibodies Market Key Insights

The market report features an extensive study of the current market landscape, market size and future opportunities within the domain of Fc and glycoengineered antibodies, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the market research report is briefly discussed below.

Pipeline Analysis: Competitive Landscape of Fc and Glycoengineered Antibodies Developers

Currently, close to 35 developers are involved in developing Fc and glycoengineered antibodies for various target indications, including atypical hemolytic uremic syndrome, bladder cancer, chronic lymphocytic leukemia and myasthenia gravis. It is worth highlighting that majority (77%) of the development programs are based on Fc engineering, within these, over 40% of the programs are being evaluated for only combination therapy. Further, around 10 Fc and glycoengineered antibodies have been commercialized for targeting various cancer indications. In addition, close to 30 Fc and glycoengineered antibodies targeting oncological disorders are under clinical development.

Market Trend Analysis: Partnerships and Collaborations have Fueled the Fc and Glycoengineered Antibodies Market Growth

In recent years, several partnerships have been established by industry stakeholders, in order to consolidate their presence in this field, and enhance their capabilities and product portfolios to meet the growing demand for Fc and glycoengineered antibodies. It is worth highlighting that over 30% of these partnerships have been inked in the past two years. Interestingly, most of the agreements signed between the stakeholders were product development and commercialization agreements, and clinical trial agreements. For instance, in February 2024, MorphoSys entered into a product development and commercialization agreement with Incyte for its drug candidate, Tafasitamab.

Clinical Trial Analysis: Close to 250 Trials are Evaluating Fc and Glycoengineered Antibodies to Treat Myriad of Disease Indications

Around 250 clinical trials have been registered across different geographical regions in order to evaluate various Fc and glycoengineered antibodies. Majority (60%) of these trials were registered in North America. Further, the maximum number of patients (150,351) were also enrolled in the trials conducted in North America, which accounts for 36% of the overall enrollment. It is worth mentioning that Pfizer is conducting the maximum number of trials in this industry for various target indications, including asthma, breast cancer, COVID-19, hepatocellular carcinoma, multiple myeloma, non-small cell lung cancer and lupus nephritis.

Fc and Glycoengineered Antibodies Market Drivers

Several factors are propelling the Fc and glycoengineered antibodies market growth. One of the key factors driving the future of this market is the growing preference for personalized healthcare, as Fc and glycoengineered antibodies can be tailored specifically to individual patients. Further, the ability of engineered antibodies to alter effector functions, such as antibody dependent cellular toxicity, enhances target specificity and safety profile of the antibody-based treatments. Additionally, owing to the increasing prevalence of various oncological and autoimmune disorders, the demand for Fc and glycoengineered antibodies is also expected to witness significant increase in the coming years.

Global Fc and Glycoengineered Antibodies Market Size

The global Fc and glycoengineered antibodies market is estimated to be worth US$ 38.8 billion in 2024. Driven by the increasing potential of these engineered antibodies as therapeutic agents, the market is anticipated to grow at a notable rate during the forecast period. Further, in terms of type of engineering, Fc engineered antibodies are likely to capture majority (93%) of the share, followed by glycoengineered antibodies (7%) within the overall market, by 2035.

Regional Analysis: North America Emerges as the Hub of Fc and Glycoengineered Antibodies Market; Asia-Pacific to be the Fastest Growing Market

Majority of the Fc and glycoengineered antibody drug developers are headquartered in North America, followed by the companies based in Europe. Currently, North America and Europe captures around 85% of the Fc and glycoengineered antibodies market share. In recent years, North America has witnessed a significant increase in R&D investments and the number of clinical studies pertaining to the development of Fc and glycoengineered antibodies. It is worth highlighting that, in the coming years, the market in Asia-Pacific is likely to grow at a higher rate, owing to the lower manufacturing costs, cheap and skilled work-force, and supportive regulatory landscape in this region.

Leading Drug Developers in the Fc and Glycoengineered Antibodies Market

Examples of key Fc and glycoengineered antibody drug developers (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, Akesobio, Alexion Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, MacroGenics, MorphoSys, Kyowa Kirin and Xencor. This market report includes an easily searchable excel database of all the companies that have the capability to offer Fc and glycoengineered antibodies.

Recent Developments in the Fc and Glycoengineered Antibodies Market

Several recent developments have taken place in the field of Fc and glycoengineered antibodies to advance targeted therapeutics, some of which have been outlined below. These developments, even if they took place post the release of the market report, substantiate the overall Fc and glycoengineered antibodies market trends that The analyst has outlined in the analysis.

• In February 2024, AbbVie acquired ImmunoGen to complement its existing oncology pipeline and drive revenue growth.
• In January 2024, AbbVie expanded its biologics manufacturing capabilities through an investment of USD 223 million at its facility based in Singapore.
• In December 2023, AstraZeneca entered into a licensing agreement with Absci to develop an AI-designed antibody for a specific oncology target.
• In August 2023, iTolerance collaborated with Northway Biotech for manufacturing of Streptavidin-FasL Fusion Protein.

Fc and Glycoengineered Antibodies Market Report Coverage

The market report presents an in-depth analysis, highlighting the various Fc and glycoengineered antibodies that are under development / have been commercialized, across different geographies. Amongst other elements, the market report includes:

• A preface providing an introduction to the full report, Fc and Glycoengineered Antibodies Market (4th Edition), till 2035.
• An outline of the systematic research methodology adopted to conduct the study on Fc and glycoengineered antibodies industry, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of the findings.
• An overview of economic factors that impact the overall Fc and glycoengineered industry, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
• An executive summary of the insights captured during the research. It offers a high-level view on the current state of Fc and glycoengineered antibodies market and its likely evolution in the mid-long term.
• A general overview of antibodies, including information on structure of antibodies, historical timeline of antibody discovery, antibody isotypes, mechanism of action of antibodies. Further, the chapter features a brief overview of the Fc region and effector functions, type of Fc receptors, engineering of the region along with details on glycoengineering, protein engineering and isotype chimerism. Furthermore, the chapter provides an overview of the future perspectives, which, we believe, are likely to influence the growth of the Fc and glycoengineered antibodies market.
• A detailed assessment of over 170 marketed / development programs that are designed for the treatment of various indications. It features a detailed analysis of Fc and glycoengineered antibodies, based on several relevant parameters, such as phase of development (marketed, clinical and preclinical), type of antibody (IgG1, IgG2, IgG2/4 and others), type of engineering (Fc engineering and glycoengineering), impact of engineering (enhanced effector function, reduced effector function and enhanced serum half-life), biological target (CD20, CD30, PD-L1 and others), type of therapy (monotherapy and combination therapy), target disease indication, therapeutic area (autoimmune disorders, infectious diseases, oncological disorders and others), route of administration (intravenous, subcutaneous and others), and popular Fc engineering technologies.
• Elaborate profiles of prominent players (shortlisted based on the proprietary criteria) in the development of Fc engineered antibodies. Each profile features a brief overview of the company (including information on year of establishment, location of headquarters, number of employees and leadership team), financial information (if available), drug portfolio, recent developments and an informed future outlook.
• An in-depth analysis of completed, ongoing, and planned clinical studies evaluating various Fc and glycoengineered antibodies, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor, most active industry players (in terms of number of trials conducted), study design, target indication and key geographical regions.
• A detailed analysis of the partnerships inked between stakeholders in this industry, since 2016, based on several parameters, such as year of partnership, type of partnership, type of engineering, therapeutic area and the most active players (in terms of the number of partnerships signed). It also presents insights related to the partnership activity, based on the regional distribution of the companies involved in these agreements.
• An in-depth analysis of grants awarded to various research institutes for projects related to Fc and glycoengineered antibodies, in the period between 2019- 2024 (till February), based on several parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, most popular NIH departments, prominent program officers, popular recipient organizations.
• An elaborate analysis of the patents that have been filed / granted for related to Fc and glycoengineering antibodies, based on the type of patent (granted patents, patent applications and others), publication year, application year, type of applicant, geographical location, CPC symbols and most active players (in terms of the number of patents filed / granted). In addition, the chapter includes patent benchmarking and an insightful patent valuation analysis, highlighting the leading patents (in terms of number of citations).
• A detailed Fc and glycoengineered antibodies market forecast in order to estimate the current market size and future opportunity over the next 11 years. Based on multiple parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market size during the forecast period 2024-2035.
• Detailed projections of the current and future opportunity within the Fc and glycoengineered antibodies market across different types of engineering, such as Fc engineered antibodies and glycoengineered antibodies.
• Detailed projections of the current and future opportunity within the Fc and glycoengineered antibody market across different types of therapy, such as monotherapy, combination therapy and both.
• Detailed projections of the current and future Fc and glycoengineered antibodies market across different therapeutic area, such as oncological disorders, rare disorders, dermatological disorders, autoimmune disorders other disorders.
• Detailed projections of the current and future opportunity within the Fc and glycoengineered antibody market across different routes of administration, such as intravenous, subcutaneous and intramuscular routes of administration.
• Detailed projections of the current and future opportunity within the Fc and glycoengineered antibodies market across key geographical regions, such as North America, Europe, Asia-Pacific and Rest of the World.
• Detailed projections of the current and future revenues from the sales of the marketed and phase III drugs in the Fc and glycoengineered antibodies market.

One of the key objectives of this Fc and glycoengineered antibodies market report was to estimate the current market size, opportunity and the future growth potential of this market, over the forecast period. Based on multiple relevant parameters, likely adoption trends and through primary validations, the analyst has provided an informed estimate on the market evolution during the forecast period 2024-2035.

The market report also features the likely distribution of the current and forecasted opportunity across various segments, such as type of engineering (Fc engineering and Fc glycoengineering), type of therapy (monotherapy, combination therapy and both), therapeutic area (autoimmune disorders, dermatological disorders, oncological disorders, rare diseases, and other disorders), route of administration (intravenous, subcutaneous, and intramuscular) and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and sales forecast. In order to account for future uncertainties associated with some of the key parameters and to add robustness to the model, the analyst has provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

Key Benefits of Buying this Report

• The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
• Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
• The report provides stakeholders with a pulse on the Fc and glycoengineered antibodies market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.